Clinical Trial

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2017-02-16; most recent amendment 2026-02-02.
Status change: Completed → Active, Not Recruiting 2026-01-21
Status change: Recruiting → Completed 2024-09-26
Status change: Not Yet Recruiting → Recruiting 2017-06-30
Trial Details
NCT Number NCT03059485
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Celgene, Dana-Farber Cancer Institute
Conditions Acute Myelogenous Leukemia
Enrollment 82 participants
Start Date 2017-06-01
Primary Completion 2026-09-04 (estimated)
Study Completion 2026-12-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-04